NDA 022122 · Haleon US Holdings
Voltaren Arthritis Pain
Diclofenac Sodium · Topical
Last checked: Nov 20, 2026Latest source record: Aug 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 17, 2007
Approved uses
2
Original approval plus efficacy supplements
Registered trials
492
123 Phase 3, 29 recruiting
FAERS reports
101,833
50,966 serious, 9,959 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 11, 2025.
Uses • for the temporary relief of arthritis pain ONLY in the following areas: o hand, wrist, elbow (upper body areas) o foot, ankle, knee (lower body areas) • this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. If no pain relief in 7 days, stop use.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 14, 2020 Supplement 14 · Efficacy LabelLetter
- Oct 17, 2007 Original approval · Type 3 - New Dosage Form ReviewLabelSummary Review
1 products under this application
- VOLTAREN ARTHRITIS PAIN · DICLOFENAC SODIUM 1% · GEL, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Diclofenac" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00250445 · 23,498 participants · Start Jan 2003 · Primary completion May 2006
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis,Osteoarthritis
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092703 · 6,000 participants · Start Jun 27, 2002 · Primary completion Nov 1, 2003
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Osteoarthritis
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092742 · 4,086 participants · Start Feb 2003 · Primary completion Dec 2005
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03304379 · 1,650 participants · Start Oct 26, 2017 · Primary completion Dec 13, 2019
Drug: Fasinumab; Matching placebo · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Anniston, Alabama; Mobile, Alabama; Chandler, Arizona · 71 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective23,949
- product use in unapproved indication11,995
- off label use10,311
- pain10,013
- fatigue9,014
- product use issue8,022
- rash7,842
- rheumatoid arthritis7,286
- product administered at inappropriate site7,061
- abdominal discomfort6,878
- arthralgia6,813
- drug effective for unapproved indication6,788
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,074 |
| 2005 | 1,133 |
| 2006 | 1,113 |
| 2007 | 1,326 |
| 2008 | 1,507 |
| 2009 | 1,550 |
| 2010 | 1,878 |
| 2011 | 2,386 |
| 2012 | 2,241 |
| 2013 | 1,114 |
| 2014 | 1,643 |
| 2015 | 3,496 |
| 2016 | 4,866 |
| 2017 | 3,849 |
| 2018 | 4,046 |
| 2019 | 3,933 |
| 2020 | 10,738 |
| 2021 | 15,424 |
| 2022 | 8,874 |
| 2023 | 9,932 |
| 2024 | 9,046 |
| 2025 | 6,972 |
| 2026 | 3,685 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.
da Costa BR, Pereira TV, Saadat P, et al. · BMJ 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Topical NSAIDs for acute musculoskeletal pain in adults.
Derry S, Moore RA, Gaskell H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis.
Xie R, Li J, Jing Y, et al. · Ann Med 2024 · Systematic Review, Network Meta-Analysis
- Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis.
Akshintala VS, Sperna Weiland CJ, Bhullar FA, et al. · Lancet Gastroenterol Hepatol 2021 · Systematic Review, Network Meta-Analysis
- Diclofenac.
Ogle C · Conn Med 1989 · Clinical Trial, Randomized Controlled Trial
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.